Improved Survival In Adults With Mixed-Phenotype Acute Leukemia Following Stem Cell Transplantation (SCT): A Single Centre Experience
Authors: Kalashetty Mallikarjun , Dalal Bakul I. , Roland Kristine J , Mourad Yasser Abou , Barnett Michael J. , Broady Raewyn , Forrest Donna L. , Hogge Donna E. , Gerrie Alina S. , Nantel Stephen H. , Power Maryse , Song Kevin W. , Sutherland Heather J. , Toze Cynthia L. , Nevill Thomas J. , Shepherd John D. , Narayanan Sujaatha 
Published: October 2019

Abstract

Background
Biphenotypic acute leukemia (BAL) is a rare subtype of leukemia accounting for 1% to 4% of all acute leukemias. They are associated with unfavorable outcome especially in adult population when treated with standard chemotherapy alone. Management issues like type of induction therapy, consolidation strategies, and role of high dose chemotherapy with stem cell transplantation remain unclear.

Methods
A retrospective review of 28 patients (pts) with BAL who were treated in Vancouver between 1984 and 2012 was performed. Diagnoses were confirmed according to WHO 2008 guidelines by two hematopathologists who independently reviewed morphology, immunophenotyping and in few cases immunohistochemistry. Kaplan-Meier estimates were utilized for event free survival (EFS) and overall survival (OAS).

Characteristics
There were 23 males and 5 females with a median age of 47 (range 17 - 75) years. Median white cell count (WCC) at presentation was 7.7 x 109(range: 0.9 to 192x109)/L. Immunophenotyping revealed “Myeloid + B-lymphoid” pattern in 13 pts (46.4%), “Myeloid + T-lymphoid” pattern in 13 pts (46.4%), “Myeloid + B-lymphoid + T-lymphoid” pattern in 1 pt (3.6%) and “T-lymphoid + B-lymhoid” pattern in 1 pt (3.6%). Cytogenetic studies revealed Normal karyotype in 6 pts (21.43%), complex karyotype in 6 pts (21.43%), Philadelphia chromosome positivity in 3 pts (10.71%), MLL rearrangement in 1 pt (3.57%) and other chromosomal abnormalities in 9 pts (32.14%). Cytogenetic studies failed in 2 pts (7.14%) and no data was available in 1 pt (3.57%).
Induction therapy was of AML type in 5 pts (17.9%), ALL type in 8 pts (28.6%), and combination of AML and ALL type in 15 pts (53.6%), and 2 of the 3 pts with Philadelphia positivity also received imatinib (one patient was treated in the pre-Imatinib era) with induction chemotherapy. Twenty (71.43%) pts achieved complete remission (CR), 16 with one cycle and 4 with two cycles. Twelve pts went on to receive high dose chemotherapy with SCT. Stem cell source was autologous in 2 pts (16.7%), related donor in 3 pts (25%), unrelated donor in 6 pts (50%), and unrelated cord blood in 1 pt (8.3%). Eleven of 12 pts were in first CR and one was in second CR before SCT. Conditioning chemotherapy was TBI-based in 7 pts and busulfan based in 5 pts.

Results
ALL treatment induced a remission in 45%, AML therapy in 0% and 53% responded to combination therapy. EFS and OAS estimates for all 28 patients at 15 years were 29% (95% CI 13% to 48%) and 40% (95% CI 21% to 58%) respectively. Patients receiving high dose chemotherapy and SCT had significantly improved OAS of 63% (95% CI 29% to 85%) vs. 23% (95%CI 6% to 46%) for those receiving only chemotherapy (P = .019). OAS for pts with presenting WCC of <30x109 was significantly better compared to pts with presenting WCC of >60x109 (54% vs. 0%, p = .039).”Myeloid + B lymphoid” group had better OAS estimates compared to “Myeloid + T- lymphoid” group (59% vs. 29% respectively, but not statistically significant, p= 0.1135). Type of induction chemotherapy, and age at diagnosis were not statistically significant outcome predictors.

Conclusion
Although a small sample size, this study would suggest that adult patients with BAL who achieve a CR with standard chemotherapy should be considered for high dose chemotherapy and stem cell transplantation. This modality of treatment gives them the greatest probability of long term overall survival.

Disclosures:
Sutherland: Celgene: Honoraria; Janssen : Honoraria; Novartis: Honoraria. Toze:Roche Canada: Research Funding; F Hoffmann-La Roche: Research Funding.